Page last updated: 2024-08-16
ro 31-8220 and pep005
ro 31-8220 has been researched along with pep005 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Akdeniz, Ö; Erin, N; Isca, VMS; Rijo, P; Tavşan, E | 1 |
Other Studies
1 other study(ies) available for ro 31-8220 and pep005
| Article | Year |
|---|---|
Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Topics: Alkanes; Animals; Bryostatins; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL2; Chemokines; Cyclopropanes; Diterpenes; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Female; Indoles; Mammary Neoplasms, Animal; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase C-delta; Protein Kinase C-epsilon; Receptors, Interleukin-8B | 2021 |